Vanguard Fiduciary Trust
MGX icon

Vanguard Fiduciary Trust’s Metagenomi Therapeutics MGX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204K Buy
171,251
+1,077
+0.6% +$1.44K ﹤0.01% 3574
2026
Q1 		$228K Buy
+170,174
New +$264K ﹤0.01% 3475

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust's MGX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Metagenomi Therapeutics (MGX) stake by 0.63% in Q2 2026, buying an estimated $1.44K and bringing the position to 171,251 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #3574.

Vanguard Fiduciary Trust first reported a position in MGX in Q1 2026 and has held it in 2 quarters since. The position peaked at $228K in Q1 2026. 40 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Vanguard Fiduciary Trust held 171,251 shares of Metagenomi Therapeutics worth $204K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 1,077 Metagenomi Therapeutics shares in Q2 2026, an estimated $1.44K.
  • Metagenomi Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3574 holding.
  • Vanguard Fiduciary Trust first reported a position in Metagenomi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Metagenomi Therapeutics position peaked at $228K in Q1 2026.
  • 40 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.